{"entity":{"id":"peptide-hla-multimer-staining","kind":"term","name":"Peptide-HLA multimer staining","aka":["peptide-MHC multimer staining","peptide-HLA tetramer staining","pMHC multimer staining"],"tldr":"This test labels cells whose receptors bind a particular displayed peptide under the assay conditions. It helps identify a binding population that can then be studied for function.","summary":"The original peptide-MHC tetramer study made soluble multimeric peptide-display complexes to identify antigen-specific T cells. Binding correlated with cytotoxicity in the tested systems, but those observations are different measurements. The chosen peptide and HLA molecule define which interaction is tested. Detecting multimer-binding cells does not by itself establish natural display of that peptide by a tumor, successful target-cell killing or a clinical treatment effect.","asOf":"2026-11-10","links":[{"label":"Phenotypic analysis of antigen-specific T lymphocytes.","url":"https://doi.org/10.1126/science.274.5284.94"},{"label":"Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation.","url":"https://doi.org/10.1016/s0022-1759(03)00265-5"},{"label":"A robust method for production of MHC tetramers with small molecule fluorophores.","url":"https://doi.org/10.1016/j.jim.2006.08.014"},{"label":"Cossarizza et al.: flow cytometry and cell sorting guidelines, third edition (2021)","url":"https://doi.org/10.1002/eji.202170126"}],"tags":[],"related":["binding-presentation-recognition","intracellular-cytokine-staining","immune-cytotoxicity-assays"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Method card, what it measures: binding of cells to a specified peptide held by a specified HLA allele, under the staining conditions. How: HLA molecules are assembled with the selected peptide and several copies are attached to a labelled scaffold (a tetramer is one format), cells are exposed and analysed, usually by flow cytometry, with viable-cell and gate selection. Input: blood or tissue cells, where staining uses a defined aliquot and compatibility with later living-cell assays depends on the preparation, and the reagent must match both peptide and allele. Thresholds: gate and positivity rules need background and reagent controls, and no universal percentage shows efficacy. Failure modes: nonspecific binding, weak binding, dead cells, a wrong or poorly formed reagent, chain differences or sampling loss. It cannot tell cytokine response, tumour-cell killing, healthy-tissue specificity or benefit.","Denominators, fictional arithmetic: 100 stained cells among 10,000 gated CD8 T cells is 1%, and the same 100 among 40,000 viable acquired cells is 0.25%. Both are correct and answer different denominator questions, and neither is a body-wide census or a killing rate. A tetramer-negative result is not a census of every possible relevant receptor, because some receptors bind too weakly for a given staining method, and HLA restriction belongs to the peptide-HLA pair and not the peptide alone.","What the evidence shows: in the original report, tetramers of HLA-A2 with two HIV-derived peptides or an influenza A matrix peptide bound peptide-specific cytotoxic T cells in vitro and T cells from the blood of HIV-infected people, and binding in general correlated well with cytotoxicity assays (Altman 1996). That is a correlation in those systems and not a rule that binding equals killing for an arbitrary tumour peptide. Tetramers are made by mixing biotinylated MHC with fluorescent streptavidin, and a later method made them with small-molecule fluorophores (Ramachandiran 2007), so reagent preparation is a source of variation. An observed stain shows binding under the tested conditions and does not show natural processing and display of that pair by a tumour.","Connecting assays is an inference task. A multimer-binding cell with no measured cytokine response need not identify one failed biological step: reagent performance, viability, stimulation, measurement window and each assay's threshold can differ. A cytokine response still does not directly measure target-cell death. Compatible cell sorting and receptor sequencing can connect binding to an operational receptor identity, but natural tumour presentation, recognition and killing remain separate questions to test.","Avidity describes the combined strength of multiple contacts. Multimerising peptide-HLA ligands can make binding detectable when an individual receptor-ligand contact is weak; the 2021 guidelines also caution that more multimerisation does not always improve detection. The measured output is a gate-defined binding fraction or, with a suitable counting method, a count. Reagent, viability and background controls support that binding measurement, which still requires separate validation before use for treatment selection."],"category":"Immunology"},"route":"/terms/peptide-hla-multimer-staining/","neighbours":{"term":[{"id":"flow-cytometry","kind":"term","name":"Flow cytometry (immunophenotyping)","route":"/terms/flow-cytometry/"},{"id":"immune-product-evidence","kind":"term","name":"Immune measurements and product evidence","route":"/terms/immune-product-evidence/"},{"id":"immune-cytotoxicity-assays","kind":"term","name":"Immune-cell cytotoxicity assays","route":"/terms/immune-cytotoxicity-assays/"},{"id":"intracellular-cytokine-staining","kind":"term","name":"Intracellular cytokine staining","route":"/terms/intracellular-cytokine-staining/"},{"id":"binding-presentation-recognition","kind":"term","name":"Peptide binding, presentation and immune recognition","route":"/terms/binding-presentation-recognition/"},{"id":"tcr-repertoire-sequencing","kind":"term","name":"T-cell receptor repertoire sequencing","route":"/terms/tcr-repertoire-sequencing/"}]}}